<DOC>
	<DOCNO>NCT01459653</DOCNO>
	<brief_summary>This international , prospective , observational , open-label , pharmaco-epidemiologic study observes cancer patient risk chemotherapy-induced febrile neutropenia ( FN ) receive filgrastim biosimilar ( EP2006 ) primary secondary FN prophylaxis well describe patient population risk FN treat prophylactically physician 's best clinical judgement filgrastim biosimilar ( EP2006 ) , describe prophylaxis pattern involve filgrastim biosimilar ( EP2006 ) , evaluate hematology level variability hematological outcome , impact chemotherapy delivery , radiotherapy , surgery , mortality . Additionally study aim identify patient cohort vulnerable poor response FN prophylaxis experience break-through episode FN , understand difference prophylaxis responder non-responders , describe degree prophylaxis FN congruence guideline recommendation .</brief_summary>
	<brief_title>Multi-level Evaluation Chemotherapy-induced Febrile Neutropenia Prophylaxis , Outcomes , Determinants With Granulocyte-colony Stimulating Factor</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<mesh_term>Chemotherapy-Induced Febrile Neutropenia</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Male female adult ( age &gt; / = 18 year ) Diagnosed one follow type stage tumor : stage III IV breast cancer ; stage III IV ovarian cancer ; stage III IV bladder cancer ; stage III IV lung cancer ; metastatic prostate cancer ; stage III IV diffuse large Bcell lymphoma ; multiple myeloma . Planned receive primary prophylaxis filgrastim biosimilar ( EP2006 ) first cycle chemotherapy ( regardless line chemotherapy ) ; receive secondary prophylaxis filgrastim biosimilar ( EP2006 ) irrespective chemotherapy cycle . Treated commercially available filgrastim biosimilar per physician 's best clinical judgment per current European filgrastim biosimilar ( EP2006 ) label . Female patient must either postmenopausal one year surgically sterile use effective contraceptive method barrier method spermicide intrauterine device . Oral contraceptive use allow . Informed write consent participate study patient legal guardian . Patients myeloid malignancy , exception multiple myeloma . Sensitivity filgrastim biosimilar CSF . Hypersensitivity E. coliderived protein . Radiotherapy â‰¥ 20 % total body bone . Infection within two week start current line chemotherapy . Patients several medical condition ( ) view investigator prohibit participation study . Patients willfully negligent nonadherence cancer treatment . Use investigational agent 30 day prior enrollment . Women childbearing potential use contraception method ( ) describe . Women breastfeed .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Febrile neutropenia</keyword>
	<keyword>cancer</keyword>
	<keyword>chemotherapy ,</keyword>
	<keyword>primary prophylaxis</keyword>
	<keyword>secondary prophylaxis</keyword>
	<keyword>filgrastim</keyword>
	<keyword>granulocyte colony stimulate factor</keyword>
	<keyword>observational study</keyword>
	<keyword>noninterventional study</keyword>
</DOC>